| Name | Title | Contact Details |
|---|
Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).
Diagenics is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.
ADMEDES SCHUESSLER GmbH is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.